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Highlights	
	
	
CaM	inhibitors	were	tested	in	unchallenged	and	in	LPS‐challenged	pure	microglia.	
	
CaM	inhibitors	affected	many	morphological	and	functional	aspects	of	these	cells.	
	
CaM,	Iba1	intracellular	distribution	and	actin	cytoskeleton	remodeling	were	
affected.	
	
CaM	inhibitors	differentially	affected	cell	proliferation	and	viability.	
	
The	inhibitors	differentially	altered	phagocytosis	in	cells	with	or	without	LPS.	
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Abstract	
	
The	roles	of	calmodulin	(CaM),	a	multifunctional	intracellular	calcium	receptor	
protein,	as	concerns	selected	morphological	and	functional	characteristics	of	pure	
microglial	cells	derived	from	mixed	primary	cultures	from	embryonal	forebrains	of	
rats,	were	investigated	through	use	of	the	CaM	antagonists	calmidazolium	(CALMID)	
and	trifluoperazine	(TFP).	The	intracellular	localization	of	the	CaM	protein	relative	
to	phalloidin,	a	bicyclic	heptapeptide	that	binds	only	to	filamentous	actin,	and	the	
ionized	calcium‐binding	adaptor	molecule	1	(Iba1),	a	microglia‐specific	actin‐
binding	protein,	was	determined	by	immunocytochemistry,	with	quantitative	
analysis	by	immunoblotting.	In	unchallenged	and	untreated	(control)	microglia,	high	
concentrations	of	CaM	protein	were	found	mainly	perinuclearly	in	ameboid	
microglia,	while	the	cell	cortex	had	a	smaller	CaM	content	that	diminished	
progressively	deeper	into	the	branches	in	the	ramified	microglia.	The	amounts	and	
intracellular	distributions	of	both	Iba1	and	CaM	proteins	were	altered	after	
lipopolysaccharide	(LPS)	challenge	in	activated	microglia.	CALMID	and	TFP	exerted	
different,	sometimes	opposing,	effects	on	many	morphological,	cytoskeletal	and	
functional	characteristics	of	the	microglial	cells.	They	affected	the	CaM	and	Iba1	
protein	expressions	and	their	intracellular	localizations	differently,	inhibited	cell	
proliferation,	viability	and	fluid‐phase	phagocytosis	to	different	degrees	both	in	
unchallenged	and	in	LPS‐treated	(immunologically	challenged)	cells,	and	
differentially	affected	the	reorganization	of	the	actin	cytoskeleton	in	the	microglial	
cell	cortex,	influencing	lamellipodia,	filipodia	and	podosome	formation.	In	summary,	
these	CaM	antagonists	altered	different	aspects	of	filamentous	actin‐based	cell	
morphology	and	related	functions	with	variable	efficacy,	which	could	be	important	
in	deciphering	the	roles	of	CaM	in	regulating	microglial	functions	in	health	and	
disease.	
	
Abbreviations	
	
Ca2+:	calcium	ion	
CALMID:	calmidazolium;	1‐[bis(4‐chlorophenyl)methyl]‐3‐[2‐(2,4‐dichlorophenyl)‐2‐
(2,4‐dichlorobenzyloxy)ethyl]‐1H‐imidazolium	chloride	
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CaM:	calmodulin	
CNS:	central	nervous	system	
DIV:	days	in	vitro	
DMEM:	Dulbecco's	Modified	Eagle's	Medium	
GAPDH:	glyceraldehyde	3‐phosphate	dehydrogenase	(EC	1.2.1.12)	
Iba1:	ionized	calcium	binding	adaptor	molecule	1	
Ki67:	proliferation	marker	antigen	identified	by	the	monoclonal	antibody	Ki67	
LPS:	bacterial	lipopolysaccharide	
mRNA:	messenger	ribonucleic	acid	
PBS:	phosphate‐buffered	saline	
RT:	room	temperature	
S.E.M.:	standard	error	of	mean	
subDIV:	subcloned	days	in	vitro	
TBS:	Tris‐buffered	saline	
TFP:	trifluoperazine;	10‐[3‐(4‐methylpiperazin‐1‐yl)propyl]‐2‐trifluoromethyl‐10H‐
phenothiazine	dihydrochloride	
TI:	transformation	index	
	
Keywords:	calmidazolium;	cell	viability;	ionized	calcium‐binding	adaptor	
molecule	1;	lipopolysaccharide;	phagocytosis;	phalloidin;	proliferation;	
trifluoperazine	
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1.	Introduction	
	
Microglia	originate	from	bone	marrow‐derived	myeloid	precursors	as	a	unique	class	
of	the	monocyte/macrophage	lineage	that	infiltrates	the	central	nervous	system	
(CNS)	during	its	early	development	(Ginhoux	et	al.,	2010;	Saijo	and	Glass,	2011).	
They	respond	rapidly	to	inflammatory	cues	and	injury	by	transforming	from	a	
ramified,	resting	state	to	an	activated,	phagocytic	ameboid	cell	type	(Kreutzberg,	
1996).	In	their	non‐activated	or	resting	state,	they	display	a	ramified	morphology	
and	subdued	macrophage‐like	functional	properties.	In	response	to	injury,	infection,	
inflammatory	or	other	signals,	the	microglia	become	activated	and	a	series	of	
morphological,	molecular	and	functional	changes	take	place	that	affect	proliferation,	
homing	and	adhesion	to	damaged	cells,	phagocytosis,	antigen	presentation	and	
cytotoxic	and	inflammation‐mediating	signaling	(Drew	and	Chavis,	2000;	Prinz	and	
Miller,	2014;	Saijo	and	Glass,	2011;	Streit	at	al.,	1999;	Town	et	al.,	2005).	
Microglial	functions	such	as	motility	and	phagocytosis	are	closely	
associated	with	dynamic	changes	in	the	cytoskeleton	and	related	to	intracellular	
calcium	(Ca2+)	signaling	(Greenberg,	1995;	Kalla	et	al.,	2003;	Mitchison	and	Cramer,	
1996).	The	ubiquitous	Ca2+‐binding	proteins	participate	in	Ca2+‐elicited	intracellular	
events,	either	as	Ca2+‐sensing/receptor/trigger	or	as	Ca2+‐buffering/transport	
proteins,	by	binding	intracellularly	stored	Ca2+	(Ikura,	1996).	They	contribute	to	
nearly	all	aspects	of	the	functioning	of	the	cell,	and	are	important	in	numerous	
intracellular	signaling	processes,	from	the	regulation	of	cellular	homeostasis	to	
learning	and	memory	(Berridge	et	al.,	2010;	Clapham,	2007).	Calmodulin	(CaM),	one	
of	the	most	important	intracellular	Ca2+	receptors,	exerts	its	biological	action	
through	its	heterogenous	population	of	target	proteins,	which	are	involved	in	a	
number	of	cellular	regulatory	processes	(Kennedy,	1989;	Palfi	et	al.,	2002).	
The	nervous	tissue	is	especially	abundant	in	CaM.	While	its	distribution	has	
been	characterized	in	detail	for	a	number	of	neuronal	cell	types	(Kovacs	and	Gulya,	
2002,	2003;	Palfi	et	al.,	1999,	2001,	2005),	its	localization	and	functions	in	glial	cells	
are	much	less	known.	Astrocytes	express	CaM	protein	in	low	quantities	(Kortvely	et	
al.,	2003),	but	mRNA	populations	from	all	three	CaM	genes	could	still	be	localized	
both	perinuclearly	and	in	the	astrocytic	endfeet	(Palfi	et	al.,	2005).	The	expression	of	
CaM	in	oligodendroglia	is	similarly	low	and	has	not	been	characterized	extensively,	
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albeit	the	regulatory	effects	of	this	protein	on	a	number	of	membrane‐bound	target	
proteins	such	as	the	myelin	basic	protein	(Libich	and	Harauz,	2008)	or	the	2',3'‐
cyclic	nucleotide	3'‐phosphodiesterase	(Myllykoski	et	al.,	2012)	have	been	
established.	Of	all	the	glial	components,	only	the	microglia	seem	to	have	a	
considerable	amount	of	CaM.	They	express	a	relatively	large	amount	of	CaM	when	
activated	(Casal	ez	al.,	2001;	Solá	et	al.,	1997),	and	many	aspects	of	their	Ca2+	
signaling	are	well	documented	(Färber	and	Kettelmann,	2006;	Wong	and	Schlichter,	
2014).	
CaM	immunoreactivity	or	CaM	gene‐specific	transcripts	are	often	
colocalized	with	those	of	the	target	enzymes	of	CaM	within	the	same	cytoplasmic	
compartments	(Erondu	and	Kennedy,	1985;	Sanabria	et	al.,	2008;	Seto‐Ohshima	et	
al.,	1983;	Strack	et	al.,	1996).	For	example,	actin	is	accompanied	by	CaM	in	the	cell	
cortex,	helping	to	remodel	the	actin‐based	cytoskeleton	in	accordance	with	the	
actual	(patho)physiological	signals	(Mitchison	and	Cramer,	1996;	Psatha	et	al.,	
2004).	Ionized	calcium‐binding	adaptor	molecule	1	(Iba1)	is	another	intracellular	
Ca2+‐binding	protein	with	actin‐binding	capability	that	is	expressed	in	macrophages	
and	microglia,	and	is	widely	used	to	detect	both	resting	and	activated	microglial	
phenotypes	(Imai	et	al.,	1996).	CaM	and	Iba1	proteins	share	a	number	of	molecular	
structural	variants	that	are	related	to	either	their	Ca2+	binding	or	their	target	
protein	recognition	(Yamada	et	al.,	2006).	In	contrast	with	the	wide‐ranging	
regulatory	roles	of	CaM,	Iba1	plays	a	much	more	restricted	role	in	microglial	
functions,	e.g.	remodeling	the	actin	cytoskeleton	during	migration	(Siddiqui	et	al.,	
2012;	Vincent	et	al.,	2012).	
	 	 The	modulatory	action	of	Ca2+‐bound	CaM	on	multiple	target	proteins	can	
be	regulated	by	a	number	of	compounds.	Calmidazolium	(CALMID;	1‐[bis(4‐
chlorophenyl)methyl]‐3‐[2‐(2,4‐dichlorophenyl)‐2‐(2,4‐dichlorobenzyloxy)ethyl]‐
1H‐imidazolium	chloride)	and	trifluoperazine	(TFP;	10‐[3‐(4‐methylpiperazin‐1‐
yl)propyl]‐2‐trifluoromethyl‐10H‐phenothiazine	dihydrochloride)	are	potent	
inhibitors	of	CaM‐related	cellular	activities	(Borsa	et	al.,	1986;	Sunagawa	et	al.,	
2000).	It	is	presumed	that,	apart	from	binding	to	the	CaM	protein	(Mashushima	et	
al.,	2000;	Vandonselaar	et	al.,	1994;	Vertessy	et	al.,	1998),	they	can	also	exert	their	
effects	on	some	of	the	CaM‐regulated	targets	directly	(Sunagawa	et	al.,	2000).	
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	 	 In	contrast	with	the	extensive	studies	on	the	involvement	of	CaM	in	a	
number	of	neuronal	phenomena,	only	limited	information	is	available	on	its	role	in	
the	development	and	maintenance	of	the	microglial	phenotype	and	its	specific	
functions.	Relatively	little	is	known,	for	example,	as	concerns	the	possible	
involvement	of	CaM	mediation	in	such	important	microglial	functions	as	
phagocytosis	and	the	cellular	functions	associated	with	it,	e.g.	dynamic	cytoskeletal	
reorganization.	Thus,	in	view	of	the	importance	of	CaM‐mediated	cell	functions	and	
the	paucity	of	data	on	specific	microglial	functions	related	to	and	possibly	regulated	
by	CaM,	we	set	out	to	investigate	the	localization	and	intracellular	distribution	of	
CaM	in	pure	microglial	cell	populations	derived	from	rat	primary	mixed	forebrain	
cultures	by	using	immunocytochemical	and	Western	blot	techniques.	Selected	CaM	
inhibitors	such	as	CALMID	and	TFP,	previously	reported	to	have	different	modes	of	
action	(Matsushima	et	al.,	2000;	Sunagawa	et	al.,	2000),	were	quantitatively	tested	
for	their	ability	to	modify	the	microglial	morphology,	lamellipodia,	filipodia	and	
podosome	formation,	and	specific	functions	such	as	cell	proliferation	and	survival,	
protein	expression	and	phagocytosis	in	unchallenged	(control)	and	
lipopolysaccharide	(LPS)‐challenged	cells.	Stimulation	with	LPS	was	used	to	
evaluate	the	ability	of	microglial	cells	to	respond	to	activation	(Fricker	et	al.,	2012;	
Song	et	al.,	2014;	Tokes	et	al.,	2011).	
	
2.	Material	and	methods	
	
All	animal	experiments	were	carried	out	in	strict	compliance	with	the	European	
Council	Directive	(86/609/EEC)	and	EC	regulations	(O.J.	of	EC	No.	L	358/1,	
18/12/1986)	regarding	the	care	and	use	of	laboratory	animals	for	experimental	
procedures,	and	followed	the	relevant	Hungarian	and	local	legislation	requirements.	
The	experimental	protocols	were	approved	by	the	Institutional	Animal	Welfare	
Committee	of	the	University	of	Szeged	(I‐74‐11/2009/MÁB).	The	pregnant	Sprague‐
Dawley	rats	(180‐200	g)	were	kept	under	standard	housing	conditions	and	fed	ad	
libitum.	
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2.1.	Antibodies 
 
The	antibodies	used	in	the	immunocytochemical	and	Western	blot	studies	are	listed	
in	Table	1.	For	a	thorough	characterization	of	different	microglial	phenotypes	
developed	in	vitro,	an	antibody	against	Iba1,	an	intracellular	actin‐	and	Ca2+‐binding	
protein	expressed	in	the	CNS	specifically	in	macrophages	and	microglia	(Imai	et	al.,	
1996;	Ahmed	et	al.,	2007),	was	used	in	our	immunocytochemical	and	Western	blot	
analyses.	An	anti‐CaM	monoclonal	antibody	was	used	to	detect	both	Ca2+‐bound	and	
Ca2+‐free	forms	of	the	antigen	(Sacks	et	al.,	1991).	The	anti‐Ki67	antibody	was	used	
to	detect	proliferating	cells.	Ki67	is	a	nuclear	protein	expressed	in	all	active	phases	
of	the	cell	cycle	from	the	late	G1	phase	through	the	end	of	the	M	phase	but	is	absent	
in	non‐proliferating	and	early	G1	phase	cells	(Scott	et	al.,	2004).	The	anti‐
glyceraldehyde	3‐phosphate	dehydrogenase	(GAPDH)	antibody	was	used	as	an	
internal	control	in	Western	blot	experiments	(Wu	et	al.,	2012).	Dilutions	of	primary	
and	secondary	antibodies,	and	also	incubation	times	and	blocking	conditions	for	
each	antibody	used	were	carefully	tested	for	both	immunocytochemistry	and	
Western	blot	analysis.	To	detect	the	specificities	of	the	secondary	antisera,	omission	
control	experiments	(staining	without	the	primary	antibody)	were	performed.	In	
such	cases,	no	fluorescent	or	Western	blot	signals	were	detected.	
	
2.2.	Preparation	of	primary	mixed	cortical	cell	cultures	
 
Mixed	primary	cortical	cell	cultures	were	established	from	embryonic	day	18	(E18)	
wild‐type	rat	embryos	by	the	use	of	the	methods	described	previously	(Szabo	and	
Gulya,	2013).	Briefly,	6‐8	fetal	rats	under	deep	ether	anesthesia	were	surgically	
decapitated	and	the	frontal	lobe	of	the	cerebral	cortex	was	removed,	minced	with	
scissors,	and	incubated	in	9	ml	Dulbecco's	Modified	Eagle's	Medium	(DMEM;	
Invitrogen,	Carlsbad,	CA,	USA)	containing	1	g/l	D‐glucose,	110	mg/l	Na‐pyruvate,	4	
mM	L‐glutamine,	3.7	g/l	NaHCO3,	10,000	U/ml	penicillin	G,	10	mg/ml	streptomycin	
sulfate	and	25	g/ml	amphotericin	B)	and	supplemented	with	0.25%	trypsin	
(Invitrogen)	for	10	min	at	37	C,	then	centrifuged	at	1,000g	for	10	min	at	room	
temperature	(RT).	The	pellet	was	resuspended	and	washed	twice	in	5	ml	DMEM	
containing	10%	heat‐inactivated	fetal	bovine	serum	(FBS;	Invitrogen)	and	
centrifuged	for	10	min	at	1,000g	at	RT.	The	final	pellet	was	resuspended	in	2	ml	of	
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the	same	solution	as	above,	after	which	the	cells	were	seeded	in	the	same	medium	
and	cultured	at	37	C	in	a	humidified	air	atmosphere	supplemented	with	5%	CO2	in	
one	or	other	of	the	following	ways:	1)	in	poly‐L‐lysine‐coated	coverslips	(18	x	18	
mm;	2	x	105	cells/coverslip)	for	immunocytochemistry;	2)	in	poly‐L‐lysine‐coated	
Petri	dishes	(60	mm	x	15	mm;	106	cells/dish)	for	Western	blot	analyses;	or	3)	in	a	
poly‐L‐lysine‐coated	culture	flask	(75	cm2	,	12	x	106	cells/flask)	for	the	subsequent	
generation	of	pure	microglial	cell	cultures.	The	mixed	primary	cultures	were	
maintained	up	to	28	days	(DIV1‐DIV28)	for	immunocytochemistry	and	Western	blot	
analyses,	and	for	7	days	(DIV7)	for	the	generation	of	pure	microglial	cells.	For	
culturing	periods	longer	than	3	days,	the	DMEM	was	changed	every	3	days.	
	
2.3.	Preparation	of	pure	microglial	cell	cultures 
 
Pure	microglial	cell	cultures	were	subcloned	from	mixed	primary	cultures	(DIV7)	
maintained	in	a	poly‐L‐lysine‐coated	culture	flask	(75	cm2	,	12	x	106	cells/flask)	by	
shaking	the	cultures	at	150	rpm	in	a	platform	shaker	for	20	min	at	37	C.	Microglia	
from	the	supernatant	were	collected	by	centrifugation	at	3,000g	for	10	min	at	RT	
and	resuspended	in	2	ml	of	DMEM/10%	FBS.	The	cells	were	seeded	at	a	density	of	2	
x	105	cells/Petri	dish	for	Western	blots	and	cell	viability	assays	or	105	
cells/coverslip/Petri	dish	for	immunocytochemistry,	proliferation	or	phagocytosis	
assays,	and	cultured	in	DMEM	in	a	humidified	atmosphere	supplemented	with	5%	
CO2	for	4	days	at	37	C.	The	medium	was	changed	on	the	first	day	after	seeding	
(subDIV1).	Immunocytochemistry	routinely	performed	on	the	pure	microglial	
cultures	4	days	after	seeding	(subDIV4)	consistently	detected	a	>99%	incidence	of	
Iba1‐immunopositive	microglial	cells	for	the	Hoechst	33258	dye‐labeled	cell	nuclei	
(Figure	2).	
	
2.4.	Treatment	of	pure	microglial	cells	with	LPS	and	CaM	inhibitors 
 
On	the	fourth	day	of	subcloning	(subDIV4),	the	DMEM	was	replaced	and	the	
expanded	pure	microglial	cells	were	treated	for	24	h	with	either	LPS	(100	ng/ml	in	
final	concentration,	dissolved	in	DMEM;	Sigma,	St.	Louis,	MO,	USA),	CALMID	(5	nM	
or	50	nM	in	final	concentration,	dissolved	in	dimethylsulfoxide	(DMSO);	Sigma)	or	
TFP	(10	M	or	20	M	final	concentration,	dissolved	in	DMSO;	Sigma)	alone,	or	with	
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a	combination	of	LPS	and	one	of	these	CaM	inhibitors,	and	the	effects	were	
compared	in	a	variety	of	morphological	and	functional	tests.	LPS	treatment	served	
as	an	immunochallenge.	Unchallenged	and	untreated	(control)	cultures	were	
maintained	under	identical	conditions,	but	without	these	inhibitors,	and	received	2	
l	DMSO	solution	instead.	
	
2.5.	Immunocytochemistry 
 
For	immunocytochemistry,	primary	cortical	cells	(DIV1‐DIV28)	or	pure	microglial	
cells	(subDIV4)	cultured	in	vitro	on	poly‐L‐lysine‐coated	coverslips	were	used.	At	
different	time	intervals	(DIV1,	DIV4,	DIV7,	DIV10,	DIV14,	DIV21,	DIV28),	or	after	
different	treatments	(subDIV4),	the	cultured	cells	on	the	coverslips	were	fixed	in	4%	
formaldehyde	in	0.05	M	phosphate‐buffered	saline	(PBS;	pH	7.4	at	RT)	for	5	min	and	
rinsed	in	0.05	M	PBS	for	3	x	5	min.	After	permeabilization	and	blocking	of	the	
nonspecific	sites	in	0.05	M	PBS	solution	containing	5%	normal	goat	serum	(Sigma),	
1%	heat‐inactivated	bovine	serum	albumin	(Sigma)	and	0.05%	Triton	X‐100	for	30	
min	at	37	C,	the	cells	on	the	coverslips	were	incubated	with	the	appropriate	
primary	antibody	(Table	1)	in	the	above	solution	overnight	at	4	C.	The	cultured	
cells	were	washed	for	4	x	10	min	at	RT	in	0.05	M	PBS,	then	incubated	with	the	
appropriate	Alexa	Fluor	fluorochrome‐conjugated	secondary	antibody	(Table	1)	in	
the	above	solution,	but	without	Triton	X‐100,	in	the	dark	for	3	h	at	RT.	The	cells	on	
the	coverslip	were	washed	for	4	x	10	min	in	0.05	M	PBS	at	RT.	At	this	stage,	the	cells	
were	occasionally	stained	with	rhodamine‐phalloidin	(5	l	in	200	l	PBS;	Molecular	
Probes,	Eugene,	OR,	USA)	for	30	min	at	RT,	then	washed	for	2	x	10	min	at	RT.	
Finally,	the	cell	nuclei	were	stained	in	a	0.05	M	PBS	solution	containing	1	mg/ml	
polyvinylpyrrollidone	and	0.5	l/ml	Hoechst	33258	dye	(Sigma).	The	coverslips	
were	rinsed	in	distilled	water	for	5	min,	air‐dried	and	mounted	on	microscope	slides	
in	Vectashield	mounting	medium	(Vector	Laboratories,	Burlingame,	CA,	USA).	Cells	
were	viewed	on	a	Nikon	Microphot‐FXA	epifluorescent	microscope	(Nikon	Corp.,	
Tokyo,	Japan)	and	photographed	with	a	Spot	RT	Color	CCD	camera	(SPOT	RT/ke,	
Diagnostic	Instruments,	Inc.,	Sterling	Heights,	MI,	USA).	
	
	
	 11
2.6.	Western	blot	analysis 
 
For	Western	blots,	the	protocols	were	optimized	for	each	antibody	as	regards	
epitope	accessibility,	polyacrylamide	gel	separation,	antibody	dilution	and	
chemiluminescence	signal	intensity.	Cultured	primary	cells	(DIV1–DIV28)	or	pure	
microglial	cells	(subDIV4)	with	different	treatment	regimens	were	collected	through	
use	of	a	rubber	policeman,	homogenized	in	50	mM	Tris‐HCl	(pH	7.5)	containing	150	
mM	NaCl,	0.1%	Nonidet	P40,	0.1%	cholic	acid,	2	μg/ml	leupeptin,	1	μg/ml	pepstatin,	
2	mM	phenylmethylsulfonyl	fluoride	and	2	mM	EDTA,	and	centrifuged	at	10,000g	
for	10	min	at	4	C.	The	pellet	was	discarded	and	the	protein	concentration	of	the	
supernatant	was	determined	(Lowry	et	al.,	1951).	For	the	Western	blot	analyses	of	
Iba1,	CaM	and	GAPDH	immunoreactivities,	5‐10	g	of	heat‐denatured	protein	was	
separated	on	an	SDS	polyacrylamide	gel.	The	stacking	gel/resolving	gel	ratio	was	4‐
10%	for	Iba1	and	GAPDH,	and	4‐16%	for	CaM	immunoreactivities;	for	CaM	
Westerns,	the	stacking	gel	was	complemented	with	16%	urea	and	16%	glycerol.	
Separated	proteins	were	then	transferred	onto	Hybond‐ECL	nitrocellulose	
membrane	(Amersham	Biosciences,	Little	Chalfont,	Buckinghamshire,	England).	
Strips	of	membranes	with	the	transferred	bands	for	CaM	and	Iba1	(both	around	17	
kDa)	and	GAPDH	(37	kDa)	were	cut	and	processed	separately	for	CaM,	Iba1	or	
GAPDH	immunodetection.	The	membranes	were	blocked	for	1	h	in	5%	nonfat	dry	
milk	(for	Iba1	and	GAPDH	Westerns)	or	5%	bovine	serum	albumin	(for	CaM	
Westerns)	in	Tris‐buffered	saline	(TBS)	containing	0.1%	Tween	20,	and	incubated	
for	1	h	with	the	appropriate	primary	antibodies	(Table	1).	After	5	washes	in	0.1%	
TBS–Tween	20,	the	membranes	were	incubated	for	1	h	with	the	appropriate	
peroxidase‐conjugated	secondary	antibodies	(Table	1),	and	washed	5	times	as	
before.	The	enhanced	chemiluminescence	method	(ECL	Plus	Western	blotting	
detection	reagents;	Amersham	Biosciences)	was	used	to	reveal	immunoreactive	
bands	according	to	the	manufacturer's	protocol.	The	immunoreactive	densities	of	
equally	loaded	lanes	were	quantified,	and	all	samples	were	normalized	to	internal	
GAPDH	load	controls	run	on	the	same	gels.	
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2.7.	Cell	proliferation	and	cell	viability	assays 
 
For	the	assessment	of	CaM	inhibition	on	cell	proliferation	and	survival,	pure	
microglial	cells	(subDIV4)	were	cultured	in	DMEM	with	or	without	the	appropriate	
test	compounds	in	a	humidified	atmosphere	supplemented	with	5%	CO2	at	37	C	for	
24	h.	To	analyze	the	effects	of	these	treatments	on	cell	proliferation,	the	cultures	
were	processed	for	Ki67	immunocytochemistry.	Proliferation	index	(PI)	was	defined	
as	the	number	of	Ki67‐positive	microglial	cell	nuclei	per	1,000	analyzed	Iba1‐
positive	cells	and	usually	expressed	as	%	of	the	total	cells	analyzed	(Brownhill	et	al.,	
2014;	Yamaguchi	et	al.,	2013).	A	total	of	1,454	fields	of	view	with	55,565	Iba1‐
positive	and	783	Ki67‐positive/Iba1‐positive	microglia	were	analyzed	across	the	
groups	(mean		S.E.M.).	
To	estimate	the	surviving	microglial	cells	after	treatments,	the	cultures	
were	washed	twice	with	2	ml	of	PBS	to	remove	cell	debris	and	treated	with	0.25%	
trypsin	solution	for	10	min	at	37	C,	collected	and	counted	in	a	Burker	cell.	The	
number	of	viable	cells	was	presented	as	mean		S.E.M.	
	
2.8.	In	vitro	phagocytosis	assay 
 
The	fluid‐phase	phagocytic	capacity	of	the	microglial	cells	was	determined	via	the	
uptake	of	fluorescent	microspheres	(2	m	in	diameter;	Sigma)	using	the	general	
methods	described	by	Szabo	and	Gulya	(2013).	Unstimulated	(control)	and	LPS‐
stimulated	pure	microglial	cell	cultures	with	or	without	CaM	inhibition	were	tested	
for	24	h.	At	the	end	of	the	culturing	period	(subDIV4),	1	l	of	a	2.5%	aqueous	
suspension	of	fluorescent	microspheres	was	added	per	ml	of	the	culture,	which	was	
then	further	incubated	for	60	min	at	37	C.	The	cells	were	next	washed	5	times	with	
2	ml	of	PBS	to	remove	dish‐	or	cell	surface‐bound	residual	fluorescent	
microspheres,	and	fixed	with	4%	formalin	in	PBS.	For	measurement	of	the	
phagocytic	activity,	Iba1‐expressing	microglia	labeled	with	phagocytosed	
microbeads	were	counted.	Negative	controls	were	treated	as	above	with	the	
exception	that	microglial	cultures	with	beads	were	incubated	for	60	min	at	4	C.	At	
this	temperature,	the	number	of	beads	associated	with	cell	surface	averaged	less	
than	1	bead	per	100	Iba1‐labeled	cells.	For	the	study	of	the	effects	of	CaM	inhibitors	
on	the	number	of	phagocytosed	beads	(mean	±	S.E.M.),	a	total	of	873	bead‐labeled	
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cells	were	counted	in	three	separate	culturing	procedures	under	a	Nikon	Microphot‐
FXA	epifluorescent	microscope	with	a	10x	or	20x	objective.	
	
2.9.	Digital	image	processing	and	image	analysis 
 
Gray	scale	digital	images	of	the	Western	blots	were	acquired	by	scanning	the	
autoradiographic	films	with	a	desktop	scanner	(Epson	Perfection	V750	PRO;	Seiko	
Epson	Corp.,	Japan).	The	images	were	scanned	and	processed	at	identical	settings	to	
allow	comparisons	of	the	Western	blots	from	different	samples.	Digital	images	were	
acquired	with	a	Nikon	Microphot‐FXA	epifluorescent	microscope	(Nikon	Corp.,	
Tokyo,	Japan),	using	a	Spot	RT	Color	CCD	camera	and	Spot	RT	software	(Spot	RT/ke	
Diagnostic	Instruments).	Microglial	cell	silhouettes	were	acquired	by	transforming	
the	raw	digital	files	of	Iba1‐immunoreactive	cells	made	under	fluorescent	
microscope	light	to	binary	files,	using	the	ImageJ	software	(version	1.47;	developed	
at	the	U.S.	National	Institutes	of	Health	by	W.	Rasband,	and	available	from	the	
Internet	at	http://rsb.info.nih.gov/ij).	The	color	cell	images	were	transformed	into	
their	binary	replicas	(silhouettes)	through	automatic	thresholding	procedures	
(Szabo	and	Gulya,	2013).	After	thresholding,	values	for	cell	perimeter	(μm)	and	cell	
area	(μm2)	were	determined	from	at	least	3	separate	experiments	(at	least	2	
coverslips	in	each	experiment	for	each	culturing	time	investigated;	about	20	
randomly	selected	cells/coverslip),	and	the	transformation	index	(TI)	reflecting	the	
degree	of	process	extension	was	calculated	via	an	expression	[perimeter	of	cell	
(μm)]2/4[cell	area	(μm2)]	as	previously	described	(Fujita	et	al.,	1996).	For	the	
analysis	of	TI	values,	a	total	of	261	cells	were	quantitatively	measured	(mean	±	
S.E.M.).	Digital	image	production	was	performed	with	Adobe	Photoshop	CS5.1	
software	(Adobe	Systems,	Inc.,	San	Jose,	CA,	USA).	Color	correction	(brightness,	
contrast)	and	cropping	of	the	fluorescent	images	were	occasionally	performed	when	
individual	photomicrographs	were	assembled	to	figure	panels	for	publication.	No	
specific	feature	within	an	image	was	enhanced,	obscured,	introduced,	moved	or	
removed.	
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2.10.	Statistical	analysis 
 
All	statistical	comparisons	were	made	with	SigmaPlot	(v.	12.3,	Systat	Software	Inc.,	
Chicago,	IL,	USA).	Results	for	the	phagocytosis	and	viability	assays	and	the	cell	
silhouette	characteristics	(TI	values)	were	analyzed	with	Kruskal‐Wallis	one‐way	
analysis	of	variance,	followed	by	Dunn's	method	for	pairwise	multiple	comparison	
procedures	for	statistically	significant	differences	between	the	groups.	For	these	
studies,	values	were	presented	as	mean	±	S.E.M.	from	at	least	three	independent	
experiments	and	p<0.05	was	considered	significant.	For	Western	blots,	values	were	
presented	as	mean	±	S.E.M.	from	at	least	three	blots,	each	representing	independent	
experiments	for	each	time	period	examined.	For	the	determination	of	the	
homogeneity	of	the	subcloned	microglial	cells,	Iba1‐positive	cells	and	Hoechst	
33258	dye‐positive	cell	nuclei	from	at	least	50	randomly	sampled	microscope	fields	
from	2‐3	coverslips	for	each	subcloned	culture	were	counted	and	the	results	are	
presented	as	mean		S.E.M.	
	
3.	Results	
	
3.1.	CaM	is	differentially	localized	in	ameboid	and	ramified	microglia	both	in	
mixed	and	pure	cultures 
 
The	quantity	and	cell	type‐specific	localization	of	the	CaM	protein	was	first	
established	in	mixed	primary	cultures	under	unstimulated	and	untreated	(control)	
conditions.	Fluorescent	immunocytochemistry	(Figure	1A‐P)	and	Western	blot	
analysis	(Figure	1Q,	R)	demonstrated	that	a	high	concentration	of	CaM	protein	was	
characteristic	of	the	mixed	cultures	throughout	culturing.	In	young	cultures	(DIV1‐
DIV7),	when	only	a	few	cells	double‐positive	for	the	Iba1	(Figure	1A,	E)	and	CaM	
(Figure	1B,	F)	antigens	existed	(Figure	1A‐H),	most	of	the	CaM	immunoreactivity	
was	associated	with	non‐microglial,	e.g.	mainly	neuronal,	cell	forms,	as	
demonstrated	earlier	(Szabo	and	Gulya,	2013).	From	DIV14	(up	to	DIV28),	as	more	
Iba1‐positive	microglia	populated	the	cultures	(Figure	1I,	M),	the	proportion	of	CaM	
immunoreactivity	associated	with	the	microglia	(Figure	1J,	N)	also	grew	steadily.	
Both	ameboid	(Figure	1A,	E)	and	ramified	microglia	(a	few	cells	in	Figure	1I,	M)	
expressed	CaM	immunoreactivity.	As	the	cultures	aged,	the	CaM	immunoreactivity	
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localized	to	microglia	became	predominant	(compare	Figure	1I,	M	with	Figure	1K,	
O).	Similarly,	Western	blot	studies	confirmed	the	increase	in	Iba1	immunoreactivity	
during	culturing	(Figure	1Q),	during	which	time	the	CaM	content	of	the	cultures	
remained	unchanged	(Figure	1R).	Thus,	by	DIV14,	the	microglia	had	become	the	
main	CaM‐expressing	cell	type	in	the	mixed	primary	forebrain	culture.	
Subsequent	experiments	were	performed	on	pure	microglial	cultures	
(subDIV4;	Figure	2).	In	these	microglial	cells	the	Iba1	immunoreactivity	was	most	
intense	in	the	lamellipodia	of	the	ameboid	forms	(Figure	3A,	D,	G),	followed	by	the	
perinuclear	region	(Figure	3D,	G).	The	strongest	CaM	immunoreactivity	was	always	
observed	in	the	ameboid	microglia,	where	the	cell	somata,	and	especially	the	
perinuclear	area,	were	the	most	intensely	labeled	(Figure	3B,	E,	H).	In	ameboid	
microglia,	the	CaM	and	Iba1	immunoreactivities	were	distributed	in	a	
complementary	manner,	as	the	Iba1	protein	tending	to	localize	in	the	cell	cortex	and	
lamellipodia	(Figure	3A,	B,	C).	The	ramified	microglia	displayed	an	almost	
homogenous	cytoplasmic	Iba1	distribution	(Figure	3J)	with	a	considerably	lower	
CaM	content	typically	localized	around	the	nucleus;	the	branches	had	only	traces	of	
CaM	immunoreactivity	(Figure	3K,	L).	
	
3.2.	CALMID	and	TFP	differentially	affect	microglial	proliferation	and	cell	
survival 
 
When	CaM	inhibitors	were	tested	on	cell	proliferation	and	cell	viability,	CALMID	and	
TFP,	either	alone	or	in	combination	with	LPS,	had	different	effects	(Figure	4A,	B).	
Proliferation	was	measured	as	a	function	of	Ki67‐immunopositivity	of	the	microglial	
cells	(PI).	Unstimulated	(control)	microglia	(subDIV4)	had	an	average	PI	value	of	
2.5%	(25.22	±	8.9	Ki67‐positive	microglia/1,000	analyzed	microglia	in	the	culture;	
Figure	4A).	LPS	challenge	inhibited	cell	proliferation,	albeit	without	reaching	
significance	(PI	=	0.41;	16.2%	of	the	control	value).	According	to	Ki67	
immunocytochemistry,	TFP10	significantly	decreased	microglial	cell	proliferation	
both	in	unchallenged	and	LPS‐challenged	microglia	with	PI	values	of	0.21%	and	
0.12%,	respectively	(Figure	4A).	While	CALMID50	treatment	alone	had	no	effect	on	
the	proliferation	of	unchallenged	microglia,	LPS‐challenged	cells	treated	with	
CALMID50	showed	some	but	not	significant	inhibition.	
	 16
Cell	viability	was	also	investigated	in	pure	microglial	cultures	(Figure	4B).	
In	contrast	with	the	ineffectivity	of	CALMID50	on	cell	survival	in	unchallenged	and	
in	LPS‐challenged	microglial	populations,	TFP10	was	highly	effective	in	these	
cultures.	In	unchallenged	cells,	TFP10	significantly	decreased	cell	viability	to	
62.47%	of	the	control	value.	Similarly,	when	the	microglial	cells	were	challenged	by	
LPS	treatment	(100	ng/ml),	TFP10	effectively	decreased	the	number	of	surviving	
cells	to	71.28%	of	the	control	(Figure	4B).	
	
3.3.	CaM	inhibition	affects	cell	morphology	and	actin	cytoskeleton	
reorganization 
 
The	microglial	morphology	in	the	control	and	experimental	groups	was	analyzed	
through	binary	silhouettes	(Figure	5).	The	quantitative	analysis	was	based	on	the	
area,	perimeter	and	TI,	the	latter	being	a	dimensionless	number	that	is	an	indicator	
for	the	degree	of	process	extension	of	a	cell.	Throughout	the	experiments,	microglial	
cells	with	TI	<	3	were	considered	ameboid.	The	unchallenged,	untreated	4‐day‐old	
pure	microglia	culture	(subDIV4)	consisted	mainly	of	ameboid	cells	(Figure	5,	
control	row;	see	also	controls	in	Figures	7,	8,	10)	with	an	average	area	of	412.91		
27.2	m2,	perimeter	of	100.73		5.4	m	and	a	TI	of	2.02		0.1	(Figure	6).	When	
administered	alone,	CALMID	and	TFP	affected	TI	and	the	microglial	cell	surface	area	
and	perimeter	differently.	For	example,	both	CALMID5	and	CALMID50	resulted	in	
increased	area,	perimeter	and	TI,	whereas	TFP	alone	strongly	inhibited	these	
characteristics.	When	challenged	with	LPS,	the	microglia	became	enlarged	and	
acquired	significantly	larger	perimeter	and	TI	(A	=	777.23		40.1	m2,	P	=	238.97		
8.6	m,	TI	=	6.14		0.4),	consistent	with	these	cells	becoming	activated	(Figures	5,	6	
and	Figure	7D‐F).	Interestingly,	CALMID5	or	CALMID50	alone	was	not	effective	but	
when	used	in	combination	with	LPS,	they	significantly	increased	the	cell	surface	
area,	perimeter	and	TI	(Figure	5,	Figure	6A,	C,	E,	Figure	7G‐I).	TFP	sigificantly	
inhibited	the	expansion	of	cell	surface	area	and	perimeter	both	in	unchallenged	and	
LPS‐challenged	cells	(Figure	6B,	D).	As	an	example,	the	cell	surface	area	was	
decreased	substantially	after	TFP	or	LPS+TFP	treatment,	to	46.4	or	44.5%	of	the	
unchallenged	or	LPS‐challenged	control	value,	respectively.	TFP	treatment	was	also	
very	effective	in	decreasing	TI,	to	25.53%	of	the	LPS‐challenged	value	(Figures	5,	6).	
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CaM	inhibition	affected	the	microglial	morphology	through	reorganization	
of	the	actin	cytoskeleton	(Figure	7).	In	unchallenged	and	untreated	(control)	
cultures,	the	Iba1‐	and	phalloidin‐related	fluorescence	signals	largely	overlapped	in	
the	cell	cortex	of	the	mainly	ameboid	microglia,	often	in	lamellipodia	(Figure	7A‐C)	
as	expected,	since	they	both	bind	to	the	actin	cytoskeleton.	When	treated	with	LPS,	
the	microglia	that	became	activated	and	enlarged	displayed	a	phalloidin	distribution	
much	fuzzier	than	that	in	the	case	of	Iba1,	probably	due	to	the	rapid	association	of	
fibrous	actin,	to	which	phalloidin	preferentially	binds	(Figure	7D‐F).	However,	spot‐
like	concentrations	of	phalloidin	fluorescence	resembling	podosomes	were	often	
visible	in	LPS‐treated	cells	(Figure	7E,	arrow).	CaM	inhibitors	affected	the	Iba1	and	
phalloidin	distributions	in	different	ways.	CALMID50	treatment	resulted	in	
phalloidin	fluorescence	that	was	clearly	distributed	in	two	distinct	concentric	rings	
in	the	cytoplasm,	one	ring	in	the	cell	cortex,	and	the	other	as	a	perinuclearly	
localized	cytoplasmic	streaming	of	freshly	synthesized	fibrous	actin	(Figure	7H,	K,	
arrows).	Phalloidin‐containing	filipodia	were	also	obvious	in	these	cells.	Similar,	
albeit	less	dense,	Iba1	distribution	was	observed	after	CALMID50	treatments	
(Figure	7G).	TFP	treatment	resulted	in	an	overlapping	and	almost	homogenous	
distribution	of	both	Iba1	immunoreactivity	and	phalloidin	fluorescence	(Figure	7M‐
O)	in	the	surviving	cells.	While	the	Iba1	immunoreactivity	remained	relatively	intact	
(Figure	7M),	most	of	the	phalloidin	fluorescence	intensity	was	lost	in	TFP‐treated	
microglia	(Figure	7N)	indicating	that	TFP	affected	actin	polymerization.	
	
3.4.	CaM	inhibitors	differentially	alter	the	intracellular	localization	of	CaM,	
and	affect	the	Iba1	and	CaM	protein	expressions 
 
CaM	inhibitors	altered	the	intracellular	localization	of	CaM	protein	(Figure	8).	Both	
unchallenged	and	untreated	cells	(Figure	8A‐C)	and	LPS‐challenged	cells	(Figure	8D‐
F)	displayed	high	CaM	content	primarily	localized	in	the	perinuclear	compartment	
and	to	a	much	lesser	extent	with	that	in	the	cell	cortex	(Figure	8A,	B).	Some	of	the	
cells	with	larger	TI	had	CaM	immunoreactivity	that	progressively	diminished	
toward	the	cell	cortex	(Figure	8C).	Interestingly,	cells	treated	with	CALMID50	alone	
displayed	a	more	heterogenously	translocated	CaM	immunoreactivity	often	
cortically	localized	in	lamellipodia	(Figure	8J‐L,	arrowheads).	In	TFP10‐treated	cells,	
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the	CaM	immunoreactivity	was	very	weak	and	homogenously	distributed	in	the	
cytoplasm	(Figure	8M‐O).	
CaM	antagonists	inhibited	Iba1	and	CaM	protein	expressions	with	different	
efficacies	(Figure	9).	In	general,	CALMID	was	less	potent	than	TFP	in	affecting	Iba1	
and	CAM	protein	expressions.	CALMID,	either	alone	or	in	combination	with	LPS,	was	
not	able	to	alter	the	Iba1	expression	significantly	(Figure	9A).	TFP	was	more	potent	
as	TFP10	and	TFP20	inhibited	Iba1	protein	expression	in	a	dose‐dependent	manner	
both	in	unchallenged	and	LPS‐challenged	cells	(Figure	9C).	Similarly	to	their	effects	
on	the	Iba1	expression,	CALMID	and	TFP	antagonized	the	CaM	protein	expression	
with	different	efficacy	(Figure	9B,	D).	When	CALMID	was	used,	the	CaM	
immunoreactivity	was	observed	to	decrease	somewhat	dose‐dependently	in	the	
unchallenged	microglia	as	CALMID50	significantly	inhibited	the	CaM	protein	
expression	to	38.6%	of	the	control	level	(Figure	9B).	Again,	TFP20	had	a	more	
profound	effect	on	the	CaM	protein	expression	(Figure	9D),	as	it	exhibited	a	strong	
inhibition	both	in	the	unchallenged	and	in	the	LPS‐activated	microglia	(20.8%	and	
23.4%	of	the	control	value,	respectively).	
	
3.5.	CaM	inhibition	impairs	phagocytosis	in	activated	microglia 
 
Cultured	microglia	readily	phagocytosed	fluorescently	labeled	beads	(Figure	10,	11).	
On	average,	unchallenged	and	untreated	microglia	had	3.13		0.1	phagocytosed	
microbeads	per	cell	(Figure	10A‐C	and	Figure	11).	LPS‐challenged	microglia	
displayed	a	large	(about	2.8‐fold)	increase	in	phagocytotic	activity	(8.78		0.3;	
Figure	10D‐F	and	Figure	11).	CaM	inhibitors	affected	phagocytosis	similarly	but	
with	different	degrees	of	potency.	CALMID	dose‐dependently	inhibited	phagocytosis	
both	in	unchallenged	and	LPS‐challenged	microglia	(Figure	10G‐I	and	Figure	11A).	
TFP	proved	to	be	a	very	strong	inhibitor	of	phagocytosis	both	in	unchallenged	and	
LPS‐challenged	microglia	(Figure	10M‐O	and	Figure	11B)	as	it	reduced	the	number	
of	phagocytosed	microbeads	by	almost	90%	(to	0.33		0.2;	10.6%	of	the	control	
value)	in	unchallenged,	and	by	76.5%	(to	0.75		0.3;	23.5%	of	the	control	value)	in	
LPS‐challenged	cells.	
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4.	Discussion 
 
One	of	the	most	ubiquitous	Ca2+‐sensing	proteins	is	CaM.	Its	distributions	in	the	
developing	and	the	adult	rodent	brain	have	been	well	documented	(Caceres	et	al.,	
1983;	Seto‐Ohshima	et	al.,	1983).	It	is	encoded	by	three	different	genes	in	mammals	
(Palfi	et	al.,	2002;	Toutenhoofd	and	Strehler,	2000).	The	expression	patterns	
corresponding	to	the	three	CaM	genes	display	a	broad	differential	distribution	in	the	
developing	(Kortvely	et	al.,	2002)	and	the	adult	rat	CNS	under	both	physiological	
(Kovacs	and	Gulya,	2002,	2003;	Palfi	et	al.,	1999;	Solá	et	al.,	1996)	and	
pathophysiological	conditions	(Palfi	et	al.,	2001;	Palfi	and	Gulya,	1999;	Vizi	et	al.,	
2000).	Quantitative	analysis	of	the	expression	patterns	of	these	genes	indicated	a	
differential	dendritic	targeting	of	the	CaM	mRNAs	(Kortvely	et	al.,	2003;	Palfi	et	al.,	
1999,	2005);	differential	intracellular	targeting	of	selected	CaM	mRNA	populations	
could	serve	for	the	local	translation	of	the	necessary	CaM	proteins	that	regulate	the	
numerous	target	proteins	in	that	particular	cytoplasmic	compartment	(Kortvely	and	
Gulya,	2004).	
	 CaM	expression	could	be	regulated	by	a	number	of	different	physiological	
and	pathophysiological	cues.	Although	its	gene	expression	is	generally	very	stable	
(Kortvely	and	Gulya,	2004;	Palfi	et	al.,	2002),	we	have	identified	many	factors	that	
could	differentially	affect	the	expressions	of	the	individual	CaM	genes	in	neurons	
with	distinct	phenotypes	from	different	brain	regions	(Orojan	et	al.,	2006;	Palfi	et	al.,	
1999,	2002;	Bakota	et	al.,	2005),	e.g.	inflammation	(Orojan	et	al.,	2008),	ischemia	
(Palfi	et	al.,	2001),	dehydration	(Palfi	and	Gulya,	1999),	and	chronic	ethanol	
treatment	and	withdrawal	(Vizi	et	al.,	2000).	Apart	from	the	neurons,	the	microglia	
display	a	considerable	amount	of	CaM.	This	CaM	expression,	however,	is	strongly	
dependent	on	the	phenotype.	After	a	kainic	acid	challenge,	CaM	immunoreactivity	
was	earlier	demonstrated	in	reactive	microglia	of	the	hippocampus	(Solá	et	al.,	
1997),	where	the	thickened	and	shortened	microglial	processes	accumulated	CaM	
protein.	
In	our	studies,	CaM	was	localized	both	in	developing	microglial	cells	of	
primary	cortical	cultures	established	from	E18	wild‐type	rat	embryos	maintained	
for	up	to	28	days	(DIV1‐28)	and	in	pure	microglial	cells	subcultured	from	DIV7	
cultures	for	4	days	(subDIV4).	Moreover,	the	presence	of	CaM	protein	was	
	 20
demonstrated	not	only	in	reactive	microglia	(treated	with	LPS	alone	or	in	
combination	with	one	of	the	CaM	inhibitors),	but	also,	at	a	lower	protein	level,	in	
unchallenged	proliferating	ameboid	or	even	ramified,	microglial	cells.	We	observed	
morphologically	and	functionally	different	microglial	populations	within	the	range	
from	weak	to	strong	levels	of	CaM	expression	during	culturing,	as	evidenced	by	their	
quantitative	assessment	by	fluorescent	immunocytochemical	and	Western	blotting	
methods.	In	mixed	primary	cortical	cultures,	ameboid	microglia,	the	predominant	
form	in	the	early	stages	but	always	present	(in	much	smaller	numbers)	during	
culturing	(Szabo	and	Gulya,	2013),	expressed	strong	CaM	immunoreactivity	
throughout	the	cytoplasm,	while	ramified	microglia,	the	typical	form	in	the	later	
stages	of	microglial	development,	showed	a	weaker	and	more	evenly	distributed	
CaM	immunoreactivity.	A	similar	intracellular	distribution	of	CaM	protein	
expression	was	observed	in	pure	microglial	cultures.	In	unchallenged	and	LPS‐
challenged	cultures,	most	of	the	microglia	was	ameboid	and	had	strong	CaM	
immunoreactivity	throughout	the	cytoplasm.	Treatments	with	CaM	inhibitors,	both	
in	unchallenged	and	LPS	challenged	cells,	resulted	in	a	weaker	and	more	
homogenously	localized	CaM	immunoreactivity.	
	 	 We	found	that	the	intracellular	localization	of	CaM	immunoreactivity	
described	above	was	closely	related,	and	typically	complementary,	to	the	
filamentous	actin	cytoskeleton,	comprised	mainly	of	branched	F‐actin	(Rotty	et	al.,	
2013).	F‐actin	was	visualized	in	our	studies	by	the	distributions	of	an	actin‐binding	
protein,	Iba1,	and	phalloidin,	a	bicyclic	heptapeptide	that	recognizes	F‐actin	only,	
e.g.	the	form	that	possesses	cellular	functionality.	Iba1	is	an	intracellular	Ca2+‐
binding	protein	that	plays	an	important	role	in	regulation	of	the	intracellular	actin	
dynamics	through	the	direct	binding	of	actin,	enhances	membrane	ruffling	and	
participates	in	phagocytosis	and	cell	motility	(Ohsawa	et	al.,	2000,	2004),	functions	
that	require	large	amounts	of	cortical	F‐actin.	Our	immunocytochemical	
observations	showed	that	ramified	cells	(characterized	by	larger	TI	values)	that	
displayed	minimal	or	no	ruffling	at	all	had	only	modest	quantities	of	CaM	proteins	in	
the	cell	cortex	as	compared	with	ameboid	or	reactive	microglia.	Coincidentally,	the	
amount	of	cortical	F‐actin	was	likewise	less	in	ramified	microglia,	and	the	
reorganization	of	the	actin	cytoskeleton	determined	the	intracellular	distribution	of	
CaM.	Concomitantly	increased	levels	of	Iba1	and	CaM	protein	expression,	however,	
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were	evident	both	in	unchallenged	ameboid	and	in	LPS‐	or	LPS	and	CaM	inhibitor‐
challenged,	e.g.	activated/reactive	microglia.	Our	observations	relating	to	the	
intracellularly	redistributed	CaM	vs.	F‐actin	are	consistent	with	the	findings	in	mast	
cells	in	previous	studies.	For	example,	Sullivan	et	al.	(2000)	demonstrated	that	CaM	
promoted	the	disassembly	of	cortical	F‐actin,	while	Psatha	et	al.	(2004)	found	that	
the	disassembly	of	the	actin	cytoskeleton	eliminated	CaM	localization.	
LPS	activation	renders	microglia	ameboid,	induces	several	pro‐	and	anti‐
inflammatory	signaling	molecules	(Lim	et	al.,	2015;	Zhu	et	al.,	2014)	and	neurotoxic	
substances	through	binding	to	the	CD14/MD‐2/Toll‐like	receptor	4‐complex	
(Fricker	et	al.,	2012;	Tokes	et	al.,	2011),	and	gives	rise,	among	others,	to	cell	
spreading	by	interfering	with	the	organization	of	the	actin	cytoskeleton	through	the	
alteration	of	integrin	clustering	(Abram	and	Lowell,	2009).	Microglia	activation	was	
shown	to	involve	the	signaling	pathways	nuclear	factor	B	and	p38	mitogen‐
activated	protein	kinase	(Bachstetter	et	al.,	2007;	Cao	et	al.,	2014;	Kaushal	et	al.,	
2007).	It	must	be	noted,	however,	that	the	activation	of	microglial	cells	by	LPS	is	not	
proliferative	(Suzumura	et	al.,	1991).	
In	our	studies,	LPS	challenge	did	not	display	a	significant	effect	on	microglial	
cell	survival	or	CaM	and	Iba1	protein	expression,	but	resulted	in	significant	cell	
spreading,	documented	in	increases	in	cell	surface,	perimeter	and	TI,	and	in	a	
repositioning	of	intracellular	actin	filaments	toward	podosome	and	filipodia	
formation.	In	spite	of	this	lack	of	interaction	between	the	LPS	challenge	and	CaM	
protein	expression,	some	of	the	effects	of	LPS	are	mediated	through	CaM‐related	
phenomena	in	macrophages	(Sweet	and	Hume,	1996).	An	LPS	challenge,	for	
example,	elevated	the	intracellular	Ca2+	concentration	in	brain	macrophages	via	the	
activation	of	phosphatidylinositol	(3,4,5)‐trisphosphate‐sensitive	stores	that,	in	
turn,	activated	the	actin	cytoskeleton	(Bader	et	al.,	1994).	Such	an	inflammatory	
response	was	recently	identified	as	one	developed	through	the	activation	of	CaM‐
dependent	kinase	kinase	2	via	Toll‐like	receptors	(Racioppi	et	al.,	2012).	Thus,	the	
effects	of	LPS	could	be	attributed,	at	least	in	part,	to	CaM‐related	phenomena	
regulating	the	actin	cytoskeleton	without	directly	affecting	the	CaM	protein	
expression.	In	another	study,	CaM	was	involved	in	spontaneous	microglial	
ramification	and	the	activation	of	proliferation	from	quiescence	as	it	inhibited	the	
spontaneous	ramification	and	decreased	the	proliferation	of	these	cells	(Casal	et	al.,	
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2001).	The	loss	of	ramification	was	reported	to	be	induced	by	the	elevation	of	
intracellular	Ca2+	via	direct	or	indirect	routes	(Kalla	et	al.,	2003)	that	eventually	
resulted	in	CaM	activation	and/or	accumulation	in	the	cell	cortex.	
A	number	of	studies	demonstrated	that	cell	cycle	and	proliferation	could	be	
regulated	by	CaM	inhibitors	(Berchtold	et	al.,	2014;	Borsa	et	al.,	1986;	Sunagawa	et	
al.,	2000).	Borsa	et	al.	(1986)	compared	the	effects	of	CALMID	and	TFP	in	cycling	
and	non‐cycling	cells	and	demonstrated	that	they	were	both	preferentially	cytotoxic	
for	cycling	cells.	Cell	proliferation	studies	on	the	osteosarcoma	cell	line	(Tseng	et	al.,	
2004),	pancreatic	beta‐cell	line	cells	(Hügl	and	Merger,	2007)	and	human	lung	
cancer	stem‐like	cells	(Yeh	et	al.,	2012)	demonstrated	that	CaM	inhibitors	effectively	
inhibited	cell	division.	TFP	inhibited	cancer	stem	cell	tumor	formation	and	growth	
through	Wnt/beta‐catenin	signaling	(Yeh	et	al.,	2012)	and	cell	migration	(Finlayson	
and	Freeman,	2009;	Linxweiler	et	al.,	2013),	and	was	shown	to	induce	apoptosis	in	
human	lung	adenocarcinoma	cell	lines	(Chen	et	al.,	2009).	In	our	proliferation	
studies,	unstimulated	microglia	(subDIV4)	exhibited	a	low	PI	value	(2.5%)	
indicating	the	presence	of	only	a	few	mitotically	active	cells.	This	value	would	not	be	
considered	a	prognostic	feature	in	a	number	of	human	cancer	types	(Brownhill	et	
al.,	2014;	Yamaguchi	et	al.,	2013).	Proliferation	was	strongly	inhibited	by	LPS	and	
TFP	as	they	reduced	the	number	of	Ki67‐positive	microglia	very	effectively.	
CALMID,	however,	had	no	effect	on	cell	proliferation	in	unchallenged	cultures,	albeit	
it	did	have	some	inhibitory	effect	in	LPS‐treated	cells.	Cell	viability	was	also	
similarly	differentially	affected	as	TFP	was	more	effective	than	CALMID	in	inhibiting	
the	survival	of	pure	microglial	cells.	
Both	CALMID	and	TFP	were	previously	shown	to	inhibit	CaM	activity	
primarily	by	binding	directly	to	the	protein	(Matsushima	et	al.,	2000;	Sunagawa	et	
al.,	2000).	However,	CALMID	and	TFP	probably	exert	many	of	their	actions	not	only	
via	their	binding	to	CaM,	but	also	by	interfering	directly	with	a	number	of	upstream	
(Qin	et	al.,	2009)	or	downstream	targets	of	CaM	signaling	(James	et	al.,	2009;	
Sunagawa	et	al.,	2000).	For	example,	the	Rho	family	GTPases,	e.g.	Cdc42,	Rac	and	
Rho,	are	known	to	be	intracellular	switches	that	regulate	remodeling	of	the	actin	
cytoskeleton	(Hall,	1998).	They	participate	in	membrane	ruffling,	lamellipodia	and	
podosome	formation	and	phagocytosis	(Dovas	et	al.,	2009;	Kanazawa	et	al.,	2002;	
Seasholtz	et	al.,	2004).	As	recent	studies	led	to	the	consculsion	that	CaM	can	regulate	
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the	activation	of	both	Rac1	and	Cdc42	in	megakaryocytes	and	platelets	(Elsaraj	and	
Bhullar,	2008;	Xu	and	Bhullar,	2011;	Xu	et	al.,	2012),	a	direct	involvement	of	CaM	in	
cytoskeleton	remodeling	was	established.	By	acting	on	a	number	of	proteins	
simultaneously,	these	CaM	antagonists	could	therefore	have	more	complex	effects,	
which	differ	from	each	other	and	may	involve	several	signaling	pathways,	thereby	
further	impairing	a	number	of	cellular	functions.	Taken	together,	these	features	
could	explain	the	differences	seen	in	the	efficacies	of	these	CaM	inhibitors	as	
concerns	various	aspects	of	microglial	morphology	and	function.	
The	ability	of	CaM	to	activate	many	target	proteins	depends	on	its	highly	
flexible	conformation,	enabling	it	to	interact	with	a	wide	variety	of	proteins	
(Yamniuk	and	Vogel,	2004).	We	hypothesize	that	this	conformational	flexibility	is	
limited	to	different	degrees	when	CaM	inhibitors	are	applied;	consequently,	many	of	
the	CaM‐regulated	effects	will	be	differentially	affected	by	CaM	inhibition.	Thus,	
given	the	number	of	CaM‐interacting	target	proteins	and	their	participation	in	the	
various	intracellular	signaling	pathways	involved	in,	for	example,	the	remodeling	of	
the	actin	cytoskeleton	during	lamellipodia,	filipodia	or	podosome	formation	(Evans	
et	al.,	2003;	Murphy	and	Courtneidge,	2011;	Sunagawa	et	al.,	2000;	Vincent	et	al.,	
2012),	cell	migration	or	phagocytosis	(Sierra	et	al.,	2013),	it	is	difficult	at	present	to	
give	an	accurate	explanation	as	to	how	different	CaM	antagonists	might	interfere	
with	the	outcome	of	the	signaling	processes.	It	seems	clear,	however,	that	CaM	
inhibition	interferes	strongly	with	both	morphological	and	functional	aspects	of	the	
microglial	cells.	Future	experiments	may	shed	light	on	whether	the	effects	of	CaM	
inhibition	seen	in	selected	morphological	and	functional	properties	of	microglia	are	
uniquely	characteristic	of	these	cells	or	may	perhaps	be	typical	of	other	cell	types	
too,	and	may	promote	an	understanding	of	the	cell	type‐specific	roles	of	CaM.	
	
5.	Conclusion	
	
CaM	is	a	key	factor	in	the	regulation	of	a	number	of	morphological	aspects	of	the	
microglia	through	the	modulation	of	the	actin	cytoskeleton	that	affects	the	
formation	and	maintenance	of	lamellipodia,	filipodia	and	podosomes	of	these	cells.	
Acting	on	many	target	proteins,	among	which	actin	is	of	paramount	importance,	it	
regulates	several	cellular	functions	such	as	phagocytosis,	cell	proliferation	and	
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survival.	CALMID	and	TFP,	two	prototypical	CaM	antagonists	acting	through	
different	molecular	mechanisms	on	the	CaM	protein,	have	differential	effects	on	
these	morphological	and	fuctional	aspects,	including	Iba1	and	CaM	protein	
expression,	when	tested	both	in	unchallenged	and	LPS‐challenged	pure	microglial	
cells.	In	general,	TFP	was	more	potent	in	provoking	these	structural	alterations	and	
functional	changes.	Dechipering	the	roles	of	CaM	in	microglial	functions,	perhaps	
through	use	of	different	CaM‐specific	inhibitors,	could	be	important	in	
understanding	the	roles	and	modes	of	action	of	microglia	in	health	and	disease.	
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Figure	1.	Development	of	Iba1	and	CaM	immunoreactivities	in	primary	mixed	
cortical	cultures	(DIV1‐DIV28).	At	early	culturing	times	(DIV1	(A‐D)	and	DIV7	(E‐
H)),	all	seeded	cells	displayed	CaM	immunoreactivity	(green),	but	only	a	few	of	them	
were	Iba1‐positive	microglia	(red).	The	cell	nuclei	(blue)	were	labeled	with	Hoechst	
33258.	Since	most	of	the	cells	present	early	in	the	culturing	are	neurons	[48],	most	
of	the	CaM	immunoreactivity	seen	at	DIV1‐DIV7	is	of	neuronal	origin.	At	DIV14	(I‐
L),	a	large	number	of	Iba1‐positive	cells	showed	CaM	positivity,	a	number	of	them	
were	ramified.	At	DIV28	(M‐P),	the	predominant	cell	type	in	the	culture	was	the	
CaM‐positive	microglia.	Note	the	visibly	different	Iba1	(M)	and	CaM	contents	(N)	of	
the	ameboid	and	ramified	microglia	at	this	culturing	time.	The	merged	pictures	
show	cells	double‐positive	for	Iba1	and	CaM	(D,	H,	L,	P).	The	development	of	Iba1	
(Q)	and	CaM	(R)	immunoreactivities	during	culturing	(DIV1‐DIV28)	was	
quantitatively	analyzed	on	Western	blots.	Protein	samples	from	primary	cultures	
were	separated	by	gel	electrophoresis,	transferred	to	nitrocellulose	membranes	and	
probed	with	either	the	Iba1	(Q)	or	CaM	(R)	antibody.	Gray	scale	digital	images	of	the	
immunoblots	were	acquired	by	scanning	the	autoradiographic	films	with	a	desktop	
scanner.	The	images	were	scanned	and	processed	at	identical	settings	to	allow	
comparisons	between	the	Western	blots	from	different	samples.	Error	bars	indicate	
integrated	optical	density	values	(mean		S.E.M.).	Representative	Western	blot	
pictures	are	shown	below	the	graphs.	During	culturing	(DIV1‐DIV28),	a	massive	
increase	in	the	number	of	cells	with	microglial	phenotype	was	observed	in	the	
mixed	primary	cultures,	while	the	CaM	content	of	the	cultures	remained	constant.	
Most	of	the	gain	in	Iba1	content	occurred	between	DIV10	and	DIV14.	Culturing	
times	are	indicated	at	the	upper	right	corners	(A,	E,	I,	M).	Scale	bar	in	A	for	all	
pictures:	50	μm.	
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Figure	2.	Localization	of	Iba1	immunoreactivity	in	pure	microglial	cell	
cultures	(subDIV4).	Representative	photomicrograph	of	Iba1	imunoreactive	
microglial	cells	in	culture.	The	purity	of	this	culture	is	close	to	100%,	since	every	
Hoechst	33258‐labeled	cell	nuclei	(blue)	is	surrounded	by	Iba1	immunopositive	
cytoplasm	(green).	Scale	bar:	100	μm.	
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Figure	3.	Distribution	of	Iba1	and	CaM	immunoreactivities	in	pure	microglial	
cells	(subDIV4).	In	pure	microglial	cultures	(subDIV4),	the	majority	of	the	
unchallenged	cells	were	ameboid	or	slightly	ramified.	While	the	Iba1	
immunoreactivity	(red)	could	be	localized	into	two	subcellular	compartments,	the	
perinuclear	and	the	cell	cortex	domains	(A,	D,	G,	J),	the	CaM	immunoreactivity	
(green)	was	largely	confined	to	the	perinuclear	region	(B,	E,	H,	K),	with	the	cell	
cortex	having	a	considerably	smaller	CaM	content,	which	progressively	diminished	
deeper	into	the	branches.	Merged	pictures	(C,	F,	I,	L)	show	the	cell	nuclei	(blue)	and	
the	overlapping	Iba1	and	CaM	immunoreactivities	predominantly	localized	to	the	
perinuclear	area.	Ameboid	microglia	have	predominantly	cortically	localized	Iba1	
immunoreactivity	in	the	leading	edges	of	large	lamellipodia	(A,	arrows),	a	
cytoplasmic	domain	largely	devoid	of	CaM	immunoreactivity	(B).	Arrowheads	(D,	
G)	point	to	large	lamellipodia.	Scale	bar	in	A	for	all	pictures:	10	μm.	
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Figure	4.	Effects	of	CaM	inhibitors	on	microglia	proliferation	and	viability	in	
pure	microglial	cell	cultures.	The	number	of	Ki67‐positive	microglia	(A)	and	the	
viable	cells	(B)	were	quantitatively	analyzed	in	challenged	and	untreated	(control),	
LPS‐challenged	and	LPS‐challenged	and	treated	cells.	CALMID	and	TFP	were	tested	
at	50	nM	and	10	M,	respectively,	either	alone	or	in	combination	with	100	ng/ml	
LPS.	TFP,	either	alone	or	in	combination	with	LPS,	significantly	decreased	both	
microglia	proliferation	(A)	and	the	number	of	viable	cells	(B)	in	the	cultures	
(subDIV4).	Interestingly,	while	the	combined	treatment	of	CALMID50	and	LPS	led	to	
some	(but	not	significant)	inhibition	on	microglia	proliferation,	it	was	without	any	
effect	on	cell	viability.	For	proliferation	studies,	data	(mean		S.E.M.)	were	collected	
from	at	least	4	independently	established	cultures,	each	involving	plating	on	at	least	
3	Petri	dishes.	Mean	PI	values	(%)	were	established	as	follows:	control	=	2.52%,	
CALMID50	=	2.48%,	TFP10	=	0.22%,	LPS	=	0.41%,	LPS+CALMID50	=	0.20%,	
LPS+TFP10	=	0.12%.	For	viability	studies,	data	(mean		S.E.M.)	were	collected	from	
at	least	3	separate	culturings,	each	involving	plating	on	at	least	6	Petri	dishes.	Data	
were	analyzed	with	Kruskal‐Wallis	one‐way	ANOVA	on	ranks,	followed	by	pairwise	
multiple	comparisons	(Dunn’s	method).	*Statistically	significant	from	control	
(p<0.05);	#statistically	significant	from	LPS‐treated	cells	(p<0.05).	LPS:	100	ng/ml;	
CALMID50:	50	nM	CALMID;	TFP10:	10	M	TFP.	
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Figure	5.	Representative	binary	silhouettes	from	pure	microglial	cultures	
after	different	treatment	regimens.	Iba1‐positive	microglial	cells	from	pure	
microglial	cultures	(subDIV4)	were	photographed,	digitized	and	quantitatively	
analyzed	according	to	their	morphological	characteristics.	Five	representative	
binary	silhouettes	are	shown	at	each	culturing	time.	CALMID50,	in	either	control	or	
LPS‐challenged	microglia,	increased	the	number	of	filipodia,	while	the	complete	
absence	of	filipodia	was	seen	both	in	TFP10	and	in	LPS+TFP10‐treated	microglia.	
Area	(A)	in	μm2,	perimeter	(P)	in	μm,	and	TI	values	(calculated	as	[perimeter	of	cell	
(μm)]2/4[cell	area	(μm2)])	are	indicated	for	each	digitized	cell.	LPS:	100	ng/ml;	
CALMID50:	50	nM	CALMID;	TFP10:	10	M	TFP.	Scale	bar	for	all	silhouettes:	50	μm.	
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Figure	6.	Effects	of	CaM	inhibitors	on	selected	morphological	parameters	of	
pure	microglial	cells.	Surface	area	(A,	B)	in	μm2,	perimeter	(C,	D)	in	μm,	and	TI	
values	(E,	F)	of	the	microglia	for	CALMID	(A,	C,	E)	and	TFP	(B,	D,	F)	were	analyzed	
in	pure	unchallenged	and	LPS‐challenged	microglial	cell	cultures.	All	statistical	
comparisons	were	made	by	using	SigmaPlot	(v.	12.3,	Systat	Software	Inc.,	Chicago,	
IL,	USA)	and	analyzed	with	Kruskal‐Wallis	one‐way	analysis	of	variance,	followed	by	
Dunn's	method	for	pairwise	multiple	comparison	procedures	for	statistically	
significant	differences	between	the	groups.	Values	(mean	±	S.E.M.)	were	computed	
from	at	least	three	independent	culturing	experiments.	*Statistically	significant	from	
control	(p<0.05);	#statistically	significant	from	LPS‐treated	cells.	LPS:	100	ng/ml;	
CALMID5:	5	nM	CALMID;	CALMID50:	50	nM	CALMID;	TFP10:	M	TFP.	
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Figure	7.	Immunocytochemical	localization	of	actin‐binding	proteins	in	pure	
microglial	cells.	Iba1	immunoreactivity	(A,	D,	G,	J,	M;	shown	here	in	green)	and	
phalloidin	fluorescence	(B,	E,	H,	K,	N;	shown	in	red)	were	colocalized	in	
unchallenged	and	untreated	(control)	cells	and	in	microglia	treated	with	LPS	or	CaM	
inhibitors	in	pure	microglial	cultures	(subDIV4).	Merged	pictures	(C,	F,	I,	L,	O)	show	
the	Hoechst	33258‐labeled	cell	nuclei	(blue)	and	the	colocalization	of	Iba1	
immunoreactivity	and	phalloidin	fluorescence.	Filamentous	actin	often	forms	
continuous	ring‐like	lamellipodia	in	unchallenged	microglia	(B).	In	LPS‐challenged	
microglial	cells,	lamellipodia	were	less	dominant,	but	the	toxin	stimulated	podocyte	
formation,	as	indicated	by	several	puncta	delineated	by	phalloidin	fluorescence	
(arrow,	E).	When	CALMID50	was	used,	strong	lamellipodia	formation	was	observed,	
often	accompanied	by	a	perinuclear	cytoplasmic	streaming	of	filamentous	actin	
(arrows,	H,	K),	giving	a	double‐ringed	appearance	of	these	cells.	TFP	treatment	
abolished	the	formation	of	filamentous	actin	bundles	as	detected	by	phalloidin	
fluorescence	microscopy	(N).	LPS:	100	ng/ml;	CALMID50:	50	nM	CALMID;	TFP10:	
10	M	TFP.	Scale	bar	in	panel	A	for	all	pictures:	50	μm.	
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Figure	8.	Effects	of	CaM	inhibitors	on	the	intracellular	localization	of	CaM	
immunoreactivity	in	pure	microglial	cells.	Representative	immunocytochemical	
pictures	showing	the	intracellular	distribution	of	CaM	immunopositivity	(red)	in	
pure	microglia	cells	(subDIV4).	The	merged	pictures	show	the	cell	nuclei	(blue)	that	
were	stained	with	Hoechst	33258.	The	unchallenged	and	untreated	(control)	
microglia	(A‐C)	and	LPS‐challenged	cells	(D‐F)	showed	mainly	perinuclearly	
localized	CaM	immunoreactivity.	LPS‐challenged	and	treated	cells	(G‐I),	and	more	
typically	CALMID50‐treated	microglia	(J‐L)	displayed	CaM	distribution	often	more	
targeted	to	the	cell	cortex	and	developing	lamellipodia	(arrowheads).	TFP	treatment	
resulted	in	a	significant	cell	death	(see	Figure	4)	and	a	homogenous	cytoplasmic	
distribution	of	CaM	immunoreactivity	in	the	surviving	microglia	(M‐O).	LPS:	100	
ng/ml;	CALMID50:	50	nM	CALMID;	TFP10:	10	M	TFP.	Scale	bar	in	panel	A	for	all	
pictures:	50	μm.	
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Figure	9.	Effects	of	CaM	inhibitors	on	Iba1	and	CaM	protein	expression	in	pure	
microglial	cells,	as	detected	by	Western	blot	analysis.	Quantitative	Western	blot	
analysis	of	Iba1	(A,	C)	and	CaM	(B,	D)	immunoreactivities	in	pure	microglial	cell	
cultures	(subDIV4).	Representative	Western	blot	pictures	of	the	respective	
immunoreactivities	are	shown	below	the	graphs	together	with	the	GAPDH	
immunoreactive	bands	that	served	as	inner	standards	in	the	same	gel.	Protein	
samples	were	collected	from	3	separate	culturings,	each	involving	plating	on	at	least	
6	Petri	dishes,	electrophoresed	and	quantitatively	analyzed	as	described	in	the	
Materials	and	methods	section.	The	integrated	optical	density	data	(mean		S.E.M.),	
normalized	to	GAPDH	immunoreactivities,	were	analyzed	with	Kruskal‐Wallis	one‐
way	ANOVA	on	ranks,	followed	by	pairwise	multiple	comparisons	(Dunn’s	method).	
*Statistically	significant	from	control	(p<0.05);	#statistically	significant	from	LPS‐
treated	cells.	Iba1:	ionized	calcium‐binding	adaptor	molecule	1;	CaM:	calmodulin;	
LPS:	100	ng/ml;	CALMID5	and	CALMID50:	5	and	50	nM	CALMID;	TFP10	and	TFP20:	
10	and	20	M	TFP;	GAPDH:	glyceraldehyde	3‐phosphate	dehydrogenase.	
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Figure	10.	Effects	of	CaM	inhibitors	on	the	phagocytic	activity	of	microglial	
cells	in	pure	microglial	cultures.	Distribution	of	phagocytosed	microbeads	in	pure	
microglial	cultures.	Representative	pictures	showing	Iba1‐immunopositive	
microglia	demonstrate	that	the	unstimulated	and	untreated	(control)	(A‐C),	LPS‐
challenged	(D‐F),	LPS	+	CALMID50‐treated	(G‐I),	CALMID50‐treated	(J‐L)	and	
TFP10‐treated	(M‐O)	microglia	displayed	different	degrees	of	phagocytosis,	as	
evidenced	by	the	number	of	phagocytosed	microbeads.	Fluorescent	dye‐coated	latex	
microbeads	(d	=	2	μm)	(green)	were	added	to	the	media	and	phagocytosed	by	
microglial	cells.	After	exposure	to	the	fluorospheres,	the	culture	was	rinsed,	the	cells	
were	formalin‐fixed,	labeled	first	with	anti‐Iba1	antibody	(red),	and	then	with	Alexa	
Fluor	fluorochrome‐conjugated	secondary	antibody,	and	the	cell	nuclei	(blue)	were	
stained	with	Hoechst	33258.	LPS:	100	ng/ml;	CALMID50:	50	nM	CALMID;	TFP10:	10	
M	TFP.	Scale	bar	in	panel	A	for	all	pictures:	50	μm.	
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Figure	11.	Effects	of	CaM	inhibitors	on	the	phagocytic	activity	of	microglial	
cells	in	pure	microglial	cultures.	Quantitative	analysis	of	the	number	of	
phagocytosed	microbeads	after	treatment	with	CALMID	(A)	or	TFP	(B)	in	
unchallenged	and	in	LPS‐challenged	microglial	cells.	For	the	study	of	the	effects	of	
CaM	inhibitors	on	the	number	of	phagocytosed	beads	(mean	±	S.E.M.),	a	total	of	873	
bead‐labeled	cells	were	counted	in	three	separate	culturing	procedures.	Data	were	
analyzed	with	Kruskal‐Wallis	one‐way	ANOVA	on	ranks,	followed	by	pairwise	
multiple	comparisons	(Dunn’s	method).	*Statistically	significant	from	control	
(p<0.05);	#statistically	significant	from	LPS‐treated	cells.	LPS:	100	ng/ml;	CALMID5:	
5	nM	CALMID;	CALMID50:	50	nM	CALMID;	TFP10:	10	M	TFP.	
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Tables	
Table	1.	Antibodies	used	in	immunocytochemistry	and	Western	blot	analyses	
	
Antibodies	used	in	immunocytochemistry	
	
Primary	
antibody,	
abbrev.	
name	
Full	name	 Final	
dilution	
Company	
name	
Secondary	
antibody	with	
fluorochrome	
Final	
dilution	
Iba1	 Rabbit	anti‐Iba1	
monocl.	ab.	
1/300	 Wako,	Osaka,	
Japan	
Alexa	Fluor	568	
goat	anti‐rabbit,	
Invitrogen,	
Carlsbad,	CA,	USA	
1/1,000	
Iba1	 Rabbit	anti‐Iba1	
monocl.	ab.	
1/300	 Wako,	Osaka,	
Japan	
Alexa	Fluor	488	
goat	anti‐rabbit,	
Invitrogen,	
Carlsbad,	CA,	USA	
1/1,000	
CaM	 Mouse	anti‐CaM,	
monocl.	ab.	
1/100	 Millipore	 Alexa	Fluor	488	
goat	anti‐mouse,	
Invitrogen,	
Carlsbad,	CA,	USA	
1/1,000	
CaM	 Rabbit	anti‐CaM,	
monocl.	ab.,	
clone	EP799Y	
1/100	 Abcam,	
Cambridge,	UK
Alexa	Fluor	568	
goat	anti‐rabbit,	
Invitrogen,	
Carlsbad,	CA,	USA	
1/1,000	
Ki67	 Rabbit	anti‐
Ki67,	monocl.	
ab.,	clone	SP6	
1/100	 Thermo	
Scientific,	
Fremont,	CA,	
USA	
Alexa	Fluor	488	
goat	anti‐rabbit,	
Invitrogen,	
Carlsbad,	CA,	USA	
1/1,000	
	
Antibodies	used	in	Western	studies	
	
Primary	
antibody,	
abbrev.	
name	
Full	name	 Final	
dilution	
Company	
name	
Secondary	
antibody	
Final	
dilution	
Iba1	 Rabbit	anti‐Iba1	
monocl.	ab.	
1/1,000	 Wako,	Osaka,	
Japan	
Anti‐rabbit	IGG,	
peroxidase	conjug.,	
Sigma,	St.	Louis,	
MO,	USA	
1/2,000	
CaM	 Rabbit	anti‐CaM,	
monocl.	ab.,	
clone	EP799Y	
1/2,000	 Abcam,	
Cambridge,	
UK	
Anti‐rabbit	IGG,	
peroxidase	conjug.,	
Sigma,	St.	Louis,	
MO,	USA	
1/2,000	
GAPDH	
	
Mouse	anti‐
GAPDH,	monocl.	
ab.,	clone	
GAPDH‐71.1	
1/20,000 Sigma,	St.	Louis,
MO,	USA	
Anti‐mouse	IGG,	
peroxidase	conjug.,	
Sigma,	St.	Louis,	
MO,	USA	
1/3,000	
